SNY vs. NVO, AZN, NVS, GSK, TAK, ARGX, BNTX, TEVA, BGNE, and GMAB
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.
Sanofi vs.
Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
In the previous week, Novo Nordisk A/S had 57 more articles in the media than Sanofi. MarketBeat recorded 64 mentions for Novo Nordisk A/S and 7 mentions for Sanofi. Sanofi's average media sentiment score of 0.63 beat Novo Nordisk A/S's score of 0.61 indicating that Sanofi is being referred to more favorably in the media.
14.0% of Sanofi shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Novo Nordisk A/S received 378 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.88% of users gave Novo Nordisk A/S an outperform vote while only 61.25% of users gave Sanofi an outperform vote.
Novo Nordisk A/S has a net margin of 35.03% compared to Sanofi's net margin of 9.96%. Novo Nordisk A/S's return on equity of 86.32% beat Sanofi's return on equity.
Sanofi currently has a consensus target price of $57.50, suggesting a potential upside of 13.32%. Novo Nordisk A/S has a consensus target price of $140.20, suggesting a potential upside of 78.06%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.
Sanofi pays an annual dividend of $1.48 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Sanofi pays out 75.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 23.3% of its earnings in the form of a dividend.
Sanofi has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Summary
Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:SNY) was last updated on 1/20/2025 by MarketBeat.com Staff
Free SNY Stock Alerts